PICO Portalanswers from OpenAlex & ORCID
Hans Tesch
ResearcherPublications, citations & collaboration network
Hans Tesch is a researcher indexed in PICO Portal from OpenAlex & ORCID.
How many works does Hans Tesch have?
PICO Portalindexed works
Hans Tesch has 758 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Hans Tesch have?
PICO Portalcitation count
Hans Tesch has 21,249 citations in the OpenAlex counts PICO Portal stores.
What is the h-index of Hans Tesch?
PICO Portalh-index
Hans Tesch has an h-index of 67 in OpenAlex.
What is the i10-index of Hans Tesch?
PICO Portali10-index
Hans Tesch has an i10-index of 262 in OpenAlex.
What is the ORCID of Hans Tesch?
PICO Portalorcid
The ORCID for Hans Tesch is on the source record.
What is the OpenAlex record for Hans Tesch?
PICO Portalopenalex
The OpenAlex for Hans Tesch is on the source record.
What are the most-cited papers on Hans Tesch?
PICO Portalmost cited works
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
Gϋnter von Minckwitz, Andreas Schneeweiß, Sibylle Loibl, Christoph Salat, Carsten Denkert, Mahdi Rezai, Jens‐Uwe Blohmer, Christian Jackisch, Stefan Paepke, Bernd Gerber, Dirk M. Zahm, Sherko Kümmel, Holger Eidtmann, Peter Klare, Jens Huober, Serban Dan Costa, Hans Tesch, Claus Hanusch, J. Hilfrich, F Khandan, Peter A. Fasching, Bruno V. Sinn, Knut Engels, Keyur Mehta, Valentina Nekljudova, Michael Untch
Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers
Carsten Denkert, Gϋnter von Minckwitz, Jan C. Brase, Bruno V. Sinn, Stephan Gade, Ralf Kronenwett, Berit M. Pfitzner, Christoph Salat, Sherene Loi, Wolfgang Schmitt, Christian Schem, Karin Fisch, Silvia Darb‐Esfahani, Keyur Mehta, Christos Sotiriou, Stephan Wienert, Peter Klare, Fabrice André, Frederick Klauschen, Jens‐Uwe Blohmer, Kristin Krappmann, Marcus Schmidt, Hans Tesch, Sherko Kümmel, Hans‐Peter Sinn, Christian Jackisch, Manfred Dietel, Toralf Reimer, Michael Untch, Sibylle Loibl
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
S. Loibl, Michael Untch, Nicole Burchardi, Jens Huober, Bruno V. Sinn, Jens‐Uwe Blohmer, Eva‐Maria Grischke, Jenny Furlanetto, Hans Tesch, Claus Hanusch, Knut Engels, Mahdi Rezai, Christian Jackisch, Wolfgang Schmitt, Gϋnter von Minckwitz, Jörg Thomalla, Sherko Kümmel, Beate Rautenberg, Peter A. Fasching, Karsten E. Weber, Kerstin Rhiem, Carsten Denkert, Andreas Schneeweiß
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials
Carsten Denkert, Fenja Seither, Andreas Schneeweiß, Theresa Link, Jens‐Uwe Blohmer, Marianne Just, Pauline Wimberger, A Forberger, Hans Tesch, Christian Jackisch, Sabine Schmatloch, Mattea Reinisch, Erich Solomayer, Wolfgang Schmitt, Claus Hanusch, Peter A. Fasching, Kristina Lübbe, Christine Solbach, Jens Huober, Kerstin Rhiem, Frederik Marmé, Toralf Reimer, Marcus Schmidt, Bruno V. Sinn, Wolfgang Janni, Elmar Stickeler, Laura L. Michel, Oliver Stötzer, Eric Hahnen, Jenny Furlanetto, Sabine Seiler, Valentina Nekljudova, Michael Untch, Sibylle Loibl
Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study
Michael Untch, Mahdi Rezai, Sibylle Loibl, Peter A. Fasching, Jens Huober, Hans Tesch, Ingo Bauerfeind, J. Hilfrich, Holger Eidtmann, Bernd Gerber, Claus Hanusch, Thorsten Kühn, Andreas du Bois, Jens‐Uwe Blohmer, Christoph Thomssen, Serban Dan Costa, Christian Jackisch, Manfred Kaufmann, Keyur Mehta, Gϋnter von Minckwitz